Janssen Pharmaceuticals and Vertex Pharmaceuticals have entered into an exclusive licence agreement to develop, manufacture and commercialise VX-787, an investigational medicine for treatment of influenza A.

VX-787 is an influenza A-specific, oral polymerase inhibitor developed to directly inhibit replication of the influenza A virus, including recent H1 and H5 influenza strains, based on in-vitro data.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the terms of the licensing agreement, Janssen also has the rights to develop, manufacture and commercialise VX-787’s back-up compound, VX-353, for treatment of influenza. Janssen has additional rights for these activities for certain other back-up compounds for treating and preventing this disease.

"This treatment has the potential to address a significant unmet medical need and to improve the well-being of patients everywhere."

VX-787 is currently in Phase II development and Vertex completed a Phase IIA study of VX-787 in 2013. The Phase IIA challenge study showed statistically significant improvements in viral and clinical measurements of influenza A infection and demonstrated clinical proof-of-concept.

Janssen and Vertex anticipate additional clinical trials to begin in the coming months.

Janssen infectious diseases and vaccines global therapeutic area head Johan Van Hoof said: "This treatment has the potential to address a significant unmet medical need and to improve the well-being of patients everywhere."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Vertex, VX-787 has showed potent and rapid in-vitro antiviral activity on all the company tested influenza A strains to date, including oseltamivir (Tamiflu) resistant strains. Initial clinical assessments of VX-787 have also been promising.

In Phase I studies, the molecule was well-tolerated in healthy volunteers providing a pharmacokinetic profile supportive of once-daily dosing.